The long‑awaited results of SURPASS‑CVOT were recently published in the New England Journal of Medicine, marking a major advance in the evidence base for incretin‑based therapy for patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). AACE Past President Scott D. Isaacs, MD, FACP, FACE, highlights that this was the first randomized, prospective cardiovascular outcomes trial to show that tirzepatide delivers cardiovascular benefits that extend beyond glycemic control and weight reduction in a high‑risk secondary‑prevention population. Read the full article on Doc Wire News to learn more.